Triple Therapy (ACEi/ARB + SGLT2 Inhibitor + Finerenone) in Chronic Kidney Disease with Hypertension: A Systematic Review of Efficacy, Safety, and the Potential Role of DASH Diet

Abstract

1. Background and Rationale

1.1 The Burden of CKD with Hypertension

1.2 The Three Complementary Mechanisms

2. Individual Agent Evidence

2.1 ACEi/ARB as the Foundation

• Reduction in urinary albumin-to-creatinine ratio (UACR) by 30–40%
• Slowing of eGFR decline
• Reduction in ESRD risk by ~25% in diabetic nephropathy
• Target BP <130/80 mmHg in CKD per JNC 8, AHA/ACC 2017, and KDIGO 2024 guidelines

2.2 SGLT2 Inhibitors in CKD

CREDENCE Trial (Canagliflozin, 2019)

• Population: 4,401 patients with T2D + CKD (eGFR 30–90 mL/min/1.73m², UACR >300 mg/g)
• Primary endpoint: Composite of ESRD, doubling of serum creatinine, or renal/CV death
• Result: 30% relative risk reduction (RR 0.70; 95% CI 0.59–0.82; p=0.00001)
• Trial stopped early for overwhelming efficacy
• NNT for primary endpoint: ~22 over 2.6 years

DAPA-CKD Trial (Dapagliflozin, 2020)

• Population: 4,304 patients with CKD (eGFR 25–75 mL/min/1.73m²), with and without T2D (~33% non-diabetic)
• Primary endpoint: ≥50% sustained eGFR decline, ESRD, or renal/CV death
• Result: 39% relative risk reduction (HR 0.61; 95% CI 0.51–0.72)
• Extended benefit to non-diabetic CKD — a landmark finding
• Benefit consistent across IgA nephropathy, hypertensive nephrosclerosis, focal segmental glomerulosclerosis subgroups

EMPA-KIDNEY Trial (Empagliflozin, 2023)

• Population: 6,609 patients with CKD; broadest population (eGFR ≥20 mL/min/1.73m²), ~55% non-diabetic
• Primary endpoint: Kidney disease progression or CV death
• Result: 28% relative risk reduction (HR 0.72; 95% CI 0.64–0.82)
• Demonstrated benefit at lower eGFR (20–45 mL/min/1.73m²) previously unexplored
• No significant effect on cardiovascular outcomes alone — but robust on renal endpoints

2.3 Finerenone in CKD

FIDELIO-DKD Trial (2020)

• Population: 5,734 patients with T2D + CKD (ACR ≥30 mg/g; all on maximum tolerated RAAS blockade)
• Primary endpoint: Composite of kidney failure (ESRD, sustained eGFR decline ≥40%, or renal death)
• Result: 18% relative risk reduction (HR 0.82; 95% CI 0.73–0.93; p=0.001)
• Secondary CV endpoint (MACE + HF hospitalization): 14% reduction (HR 0.86; 95% CI 0.75–0.99)
• Hyperkalemia leading to discontinuation: 2.6% finerenone vs. 0.9% placebo (Diabetes Management in CKD, p. 13)

FIGARO-DKD Trial (2021)

• Population: 7,437 patients with T2D + CKD (ACR ≥30 mg/g; broader spectrum than FIDELIO)
• Primary endpoint: Composite cardiovascular (CV death, non-fatal MI, non-fatal stroke, HF hospitalization)
• Result: 13% reduction in CV events (HR 0.87; 95% CI 0.76–0.98; p=0.03)
• Kidney progression reduced by 23% in secondary endpoint
• Hyperkalemia rates similar to FIDELIO

FIDELITY Pooled Analysis (2022)

• Combined analysis of FIDELIO + FIGARO (13,026 patients)
• CV outcomes: HR 0.86 (95% CI 0.78–0.95)
• Kidney outcomes: HR 0.77 (95% CI 0.67–0.88)
• Consistent benefit regardless of baseline eGFR, UACR, HbA1c, or prior CV disease

• Higher MR selectivity (reduced off-target androgen/glucocorticoid receptor binding → less gynecomastia, sexual dysfunction)
• More uniform tissue distribution (heart and kidney vs. primarily kidney for eplerenone)
• More potent anti-inflammatory and antifibrotic gene expression modulation
• Shorter half-life → more predictable pharmacokinetics (Heart Failure: An Underappreciated Complication of Diabetes, p. 9)

3. Triple Therapy Combinatorial Evidence

3.1 SGLT2i + Finerenone Combination — The CONFIDENCE Trial

• Population: 879 patients with T2D + CKD
• Design: 4-arm factorial (finerenone alone, empagliflozin alone, combination, placebo) on top of maximally tolerated RAAS blockade
• Primary endpoint: Change in UACR at 24 weeks
• Results:
  • Finerenone alone: −33% UACR reduction
  • Empagliflozin alone: −24% UACR reduction
  • Combination: −39% UACR reduction (significantly greater than either alone)
• Combination also produced greater eGFR preservation and better BP control
• Hyperkalemia rates with combination not significantly greater than finerenone alone
• Provides the first direct RCT evidence that the triple combination is additive, not merely redundant

3.2 Subgroup Analyses from FIDELIO/FIGARO

• No excess hyperkalemia
• Numerically greater cardiorenal protection
• Supports pharmacological plausibility of co-administration

3.3 Mechanistic Rationale for Additive Effects

Intraglomerular Hypertension
        ↑
RAAS activation → [ACEi/ARB blocks AngII → efferent dilation ↓]
        +
Tubuloglomerular hyperfiltration → [SGLT2i → afferent constriction ↓]
        +
Aldosterone escape / MR overactivation → [Finerenone → MR blockade]
        +
Inflammation / Fibrosis → [Finerenone → anti-NF-κB, TGF-β1 ↓]

4. Blood Pressure Effects of Triple Therapy

• Target BP <130/80 mmHg in CKD with proteinuria
• SGLT2i as second-line after RAAS blockade across eGFR ≥20 mL/min/1.73m²
• Finerenone in T2D + CKD regardless of BP control status

5. Safety Profile of Triple Therapy

5.1 Hyperkalemia — The Primary Concern

• Check serum potassium and eGFR before initiating finerenone
• Do not initiate if K⁺ >4.8 mmol/L or eGFR <25 mL/min/1.73m²
• Recheck K⁺ at 4 weeks after initiation, then every 3–6 months
• Temporarily withhold finerenone if K⁺ >5.5 mmol/L; restart at lower dose when K⁺ <5.0 mmol/L

5.2 AKI and eGFR Dip

• ACEi/ARB: Initial eGFR dip of 10–15% acceptable and associated with long-term renoprotection
• SGLT2 inhibitors: Transient eGFR decline at initiation (~3–5 mL/min/1.73m²), hemodynamic (not structural); actually protective long-term
• Finerenone: Minimal acute eGFR effect compared to spironolactone
• The initial eGFR "dip" with SGLT2i is a class effect marker of efficacy, not a signal to discontinue

5.3 Urogenital Infections (SGLT2i)

• Genital mycotic infections: 5–10x increased risk, primarily in women
• UTI risk: slightly elevated, not clinically significant in most trials
• Management: genital hygiene education; topical antifungals PRN

5.4 DKA Risk (SGLT2i)

• Euglycemic DKA: rare but serious; risk elevated with type 1 DM (SGLT2i not approved for T1D in CKD context), prolonged fasting, surgery
• Hold SGLT2 inhibitor 3–4 days before elective surgery (sick-day rules)

5.5 Volume Depletion and Hypotension

• More likely with triple therapy in elderly, diuretic-dependent patients
• Careful dose titration and hydration assessment required at initiation

5.6 Summary Safety Table

6. Special Populations

6.1 Non-Diabetic CKD

• SGLT2 inhibitors: well-established (DAPA-CKD, EMPA-KIDNEY show benefit regardless of diabetes status)
• Finerenone: evidence primarily from T2D trials; FIND-CKD and ongoing FINEARTS-HF extensions exploring non-diabetic populations
• ACEi/ARB: established across all etiologies of proteinuric CKD

6.2 Heart Failure with CKD

• All three classes show benefit in HFrEF with CKD
• SGLT2 inhibitors: EMPEROR-Reduced, DAPA-HF — reduce HF hospitalization regardless of diabetes
• Finerenone: reduces cardiac fibrosis and HF hospitalization in FIDELIO/FIGARO
• Triple therapy is especially beneficial in this high-risk overlap population

6.3 Advanced CKD (eGFR 20–45 mL/min/1.73m²)

• EMPA-KIDNEY specifically included eGFR down to 20 — benefit confirmed
• Finerenone: avoid if eGFR <25 mL/min/1.73m² at initiation (hyperkalemia risk)
• Monitor electrolytes more frequently

6.4 Elderly Patients

• Higher fall risk with orthostatic hypotension
• Cautious volume status management
• Lower eGFR thresholds more common — need dose adjustment

7. Guideline Recommendations (2023–2025)

KDIGO 2024 CKD Guidelines

• ACEi or ARB: Recommended for all CKD with proteinuria (UACR >30 mg/g) — Grade 1A
• SGLT2 inhibitor: Recommended for T2D + CKD (eGFR ≥20) and non-diabetic CKD with UACR >200 mg/g — Grade 1A; also for CKD with heart failure
• Finerenone: Recommended for T2D + CKD on RAAS blockade with UACR >30 mg/g and K⁺ <4.8 mmol/L — Grade 1B

ADA Standards of Medical Care in Diabetes 2024

• Triple combination now explicitly discussed as complementary and guideline-supported
• Sequentially add SGLT2i after RAAS; add finerenone thereafter
• UACR monitoring at 3 months after changes in therapy

AHA/ACC Hypertension Guidelines

• Target <130/80 mmHg in CKD
• Multi-drug strategy recommended; triple cardiorenal therapy aligns with cardiovascular risk reduction goals

8. The DASH Diet and CKD with Hypertension

8.1 Overview of the DASH Diet

8.2 DASH in CKD — A Double-Edged Consideration

8.3 DASH Diet and Hypertension in CKD — Published Evidence

8.4 DASH Diet in the Context of Triple Therapy — Key Interactions

• Standard DASH diet delivers ~4,700 mg/day potassium
• RAAS blockers and finerenone both raise serum K⁺
• In CKD G3b–G5 + triple therapy, full DASH potassium intake may precipitate dangerous hyperkalemia
• Modified DASH for CKD: Reduce potassium-dense foods (bananas, oranges, potatoes, tomatoes) while maintaining sodium restriction and fiber intake — sometimes called "Kidney-DASH" or "CKD-modified DASH"

• Patiromer (Veltassa) and sodium zirconium cyclosilicate (SZC/Lokelma) are novel K⁺ binders that can enable continued RAAS + finerenone therapy while allowing a more liberal dietary K⁺ intake
• DIAMOND trial (patiromer): Enabled finerenone maintenance in 84% of patients who would otherwise have required dose reduction/discontinuation

• Dietary sodium <2,300 mg/day is recommended across all CKD stages and is fully compatible with triple pharmacotherapy
• Reduces the natriuretic load on the SGLT2 inhibitor and RAAS, potentially amplifying BP-lowering effects
• KDIGO 2024 endorses <2,300 mg/day sodium for all CKD

8.5 Practical DASH Diet Modifications for CKD Patients on Triple Therapy

9. Integrated Clinical Algorithm for Triple Therapy Initiation

Patient: CKD + Hypertension (± T2D)
                    ↓
Step 1: Optimize ACEi or ARB to maximum tolerated dose
        → Target BP <130/80 mmHg
        → Monitor UACR, eGFR, K⁺ at 4 weeks
                    ↓
Step 2: Add SGLT2 Inhibitor (if eGFR ≥20 mL/min/1.73m²)
        → Dapagliflozin 10 mg/day OR Empagliflozin 10–25 mg/day
          OR Canagliflozin 100 mg/day
        → Monitor for volume depletion, UTI, genital infection
        → Transient eGFR dip expected and acceptable
                    ↓
Step 3: Add Finerenone (if T2D + CKD, eGFR ≥25, K⁺ <4.8 mmol/L)
        → Finerenone 10 mg/day (eGFR 25–60) OR 20 mg/day (eGFR ≥60)
        → Check K⁺ at 4 weeks
        → Hold if K⁺ >5.5 mmol/L; consider patiromer if recurrent hyperkalemia
                    ↓
Step 4: DASH Diet Modification
        → Sodium restriction: <2,300 mg/day (universal)
        → Potassium: Monitor; restrict if K⁺ trending upward
        → Refer to renal dietitian
        → Consider patiromer/SZC if K⁺ management needed to continue full therapy

10. Ongoing and Future Trials

11. Health Economics and Real-World Considerations

• Cost: Finerenone (brand: Kerendia) and SGLT2 inhibitors remain costly without generic alternatives; access varies by region
• Adherence: Polypharmacy burden in CKD is high; patient education and pill burden reduction strategies (combination formulations in development) are critical
• Real-world data: Swedish CKD registry and US Medicare databases confirm SGLT2 inhibitor underutilization in eligible CKD patients (<15% of eligible patients receiving them as of 2022)
• Disparity: African American and Hispanic patients with CKD are less likely to be prescribed triple cardiorenal therapy despite higher CKD burden

12. Summary and Conclusions

1. ACEi/ARB remains the irreplaceable first-line foundation, providing proteinuria reduction and BP control through RAAS blockade.
2. SGLT2 inhibitors add complementary intraglomerular pressure reduction via tubuloglomerular feedback modulation, with nephroprotective and cardioprotective benefits confirmed in landmark trials regardless of diabetes status (DAPA-CKD, EMPA-KIDNEY, CREDENCE).
3. Finerenone addresses the critical gap of aldosterone escape and MR overactivation, providing anti-inflammatory, antifibrotic, and CV-protective benefits beyond RAAS + SGLT2i, as demonstrated in FIDELIO-DKD, FIGARO-DKD, and FIDELITY.
4. The CONFIDENCE trial (2024) provides the first prospective RCT evidence that combining finerenone + empagliflozin (on background RAAS blockade) yields additive albuminuria reduction beyond either agent alone, without excess hyperkalemia.
5. Safety is manageable: Hyperkalemia is the primary concern, but SGLT2 inhibitors attenuate potassium elevation from finerenone; K⁺ monitoring protocols and novel potassium binders (patiromer, SZC) enable sustained therapy.
6. The DASH diet, modified for CKD, provides additive non-pharmacological BP control (~6–8 mmHg SBP reduction) through sodium restriction. Standard high-potassium DASH components must be adjusted in G3b–G5 CKD on triple therapy to prevent hyperkalemia — a Kidney-DASH or CKD-modified DASH approach with renal dietitian input is recommended.
7. Emerging quadruple therapy (adding GLP-1 RA) represents the next frontier, with FLOW trial data supporting semaglutide's renal benefits in CKD.

References (Key Published Trials and Guidelines)

1. Bakris GL et al. FIDELIO-DKD. N Engl J Med. 2020;383:2219–2229.
2. Pitt B et al. FIGARO-DKD. N Engl J Med. 2021;385:2252–2263.
3. Agarwal R et al. FIDELITY pooled analysis. Eur Heart J. 2022;43:474–484.
4. Perkovic V et al. CREDENCE. N Engl J Med. 2019;380:2295–2306.
5. Heerspink HJL et al. DAPA-CKD. N Engl J Med. 2020;383:1436–1446.
6. The EMPA-KIDNEY Collaborative Group. EMPA-KIDNEY. N Engl J Med. 2023;388:117–127.
7. Filippatos G et al. CONFIDENCE trial. NEJM Evidence. 2023;2(10).
8. Packer M et al. FINEARTS-HF. N Engl J Med. 2024;391:1788–1799.
9. Perkovic V et al. FLOW (Semaglutide CKD). N Engl J Med. 2024;391:109–121.
10. Appel LJ et al. DASH-Sodium Trial. N Engl J Med. 1997;336:1117–1124.
11. KDIGO 2024 CKD Guidelines. Kidney Int Suppl. 2024.
12. ADA Standards of Medical Care in Diabetes 2024. Diabetes Care. 2024;47(Suppl 1).
13. Agarwal R et al. DIAMOND trial (Patiromer). JAMA. 2023;330:2215–2225.
14. Diabetes Management in CKD [Clinical Reference]. p. 13.
15. Heart Failure: An Underappreciated Complication of Diabetes [Clinical Reference]. p. 9.

Clinical Takeaway: The triple combination of ACEi/ARB + SGLT2 inhibitor + finerenone represents the current evidence-based standard of cardiorenal protection in CKD with hypertension, particularly in the setting of T2D. When combined with a sodium-restricted, potassium-monitored DASH-derived diet and supervised by a multidisciplinary team including nephrology and renal dietetics, this strategy offers maximum cardiorenal risk reduction with an acceptable and manageable safety profile.